A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

10.1200/jco.2015.33.15_suppl.5506 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5506-5506 ◽

Cited By ~ 17

Author(s):

Amit M. Oza ◽

Johanne Ingrid Weberpals ◽

Diane M. Provencher ◽

Eva-Maria Grischke ◽

Marcia Hall ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Platinum Sensitive ◽

829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.968 ◽

2020 ◽

Vol 31 ◽

pp. S624-S625

Author(s):

O. Tredan ◽

M. Provansal Gross ◽

C. Abdeddaim ◽

S. Chabaud ◽

A. Anota ◽

...

Keyword(s):

Ovarian Cancer ◽

Disease Progression ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive ◽

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.09.033 ◽

2009 ◽

Vol 112 (1) ◽

pp. 35-39 ◽

Cited By ~ 13

Author(s):

Sheng-Mou Hsiao ◽

Chi-An Chen ◽

Ho-Hsiung Lin ◽

Chang-Yao Hsieh ◽

Lin-Hung Wei

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Front Line ◽

Platinum Sensitive ◽

Line Therapy

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.

10.1200/jco.2011.29.15_suppl.5004 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5004-5004 ◽

Cited By ~ 15

Author(s):

R. T. Penson ◽

C. Whalen ◽

B. Lasonde ◽

C. N. Krasner ◽

P. Konstantinopoulos ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1638 ◽

2019 ◽

Vol 26 (5) ◽

pp. 1009-1016 ◽

Cited By ~ 12

Author(s):

Amit M. Oza ◽

Ursula A. Matulonis ◽

Angeles Alvarez Secord ◽

John Nemunaitis ◽

Lynda D. Roman ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Resistant ◽

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

10.1200/jco.2011.29.15_suppl.5045 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5045-5045 ◽

Cited By ~ 15

Author(s):

R. W. Naumann ◽

R. L. Coleman ◽

R. A. Burger ◽

T. J. Herzog ◽

R. Morris ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized phase II trial comparing IG-001 versus paclitaxel against first-line advanced ovarian cancer.

10.1200/jco.2014.32.15_suppl.5590 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5590-5590

Author(s):

Vuong N. Trieu ◽

Monica Choi ◽

Larn Hwang ◽

Osmond D'Cruz

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

First Line ◽

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mds282 ◽

2013 ◽

Vol 24 (1) ◽

pp. 145-152 ◽

Cited By ~ 50

Author(s):

S.B. Kaye ◽

C.J. Poole ◽

A. Dańska-Bidzińska ◽

L. Gianni ◽

G. Del Conte ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Platinum Sensitive ◽

Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (NCT03026062)

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00718-6 ◽

2021 ◽

Vol 162 ◽

pp. S39

Author(s):

Emily Hinchcliff ◽

Ami Patel ◽

Bryan Fellman ◽

Shannon Westin ◽

Anil Sood ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Clear Cell ◽

Phase Ii Trial ◽

Platinum Resistant ◽